Why Waters Corporation stock remains on buy lists - Risk Management & Risk Controlled Stock Alerts

FierceBiotechExecutive Interviews at Fierce Biotech Week 2026

BioWorldBiopharma money raised by month in 2026 (US$M)

BioPharma DiveStudy data convince Lundbeck to push new migraine drug forward

BioPharma DiveGeneric drugmakers gain key victory in ‘skinny label’ patent case

Endpoints NewsInnovent declares Phase 3 success for ADC that attracted huge Takeda deal

FierceBiotechAffibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejection

Clinical OMICsInfluenza Drugs Could Prevent Cognitive Decline in Chronic Viral Infections

FierceBiotechInsulet debuts latest enhancements to popular Omnipod insulin delivery system

PharmaVoiceBMS under pressure in schizophrenia; Summit/Akeso on a winning streak

Promega BlogMeasuring What Matters in Metabolic Research: A Bioluminescent Toolkit

BioWorldNME Digest: Q1 2026

FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteran